This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Low molecular weight heparin & ischaemic stroke

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There is mixed trial evidence concerning the use of low molecular weight heparin (LMWH) in patients with acute ischaemic stroke.

Some trials suggest a reduction in mortality/dependency at six months in those treated with LMWH.

However recent evidence suggests that LMWH has no significant benefit over aspirin for acute ischaemic stroke in patients with atrial fibrillation.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.